Idiopathic Pulmonary Fibrosis: Clinical Trials

308 completed, 72 recruiting, 61 unknown, 53 terminated. 153 Phase 2, 105 Phase 1, 78 Not applicable, 58 Phase 3, 12 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	153	Completed 76, Recruiting 21, Terminated 20, Active not recruiting 13, Withdrawn 9, Not yet recruiting 7, Unknown 7
Phase 1	105	Completed 77, Terminated 8, Not yet recruiting 5, Recruiting 5, Unknown 5, Active not recruiting 3, Suspended 1, Withdrawn 1
Not applicable	78	Completed 42, Unknown 15, Recruiting 11, Terminated 5, Active not recruiting 3, Not yet recruiting 2
Phase 3	58	Completed 26, Terminated 15, Recruiting 9, Not yet recruiting 3, Active not recruiting 2, Unknown 2, Enrolling by invitation 1
Phase 4	12	Completed 6, Terminated 2, Unknown 2, Withdrawn 2
Early Phase 1	10	Completed 3, Unknown 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow Idiopathic Pulmonary Fibrosis: new trials by email Literature Review of Idiopathic Pulmonary Fibrosis trials Research Report on Idiopathic Pulmonary Fibrosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis BMS-986278 - Pulmonary Fibrosis	Phase 3	Not yet recruiting	Bristol-Myers Squibb	2380	2026-12-16	2026-08-14
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis	Phase 2	Not yet recruiting	University of Alabama at Birmingham	52	2026-12-01	2026-10-20
A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis AGMB-447, Placebo - Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Not yet recruiting	Agomab Spain S.L.U.	120	2026-11-30	2026-10-07
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis CHF10073 low dose, CHF10073 high dose, Placebo - Idiopathic Pulmonary Fibrosis	Phase 1	Not yet recruiting	Chiesi Farmaceutici S.p.A.	18	2026-11-01	2026-10-21
Study of ORJ-001 for the Treatment of IPF ORJ-001, Placebo - Idiopathic Pulmonary Fibrosis	Phase 2	Recruiting	Oorja Bio, Inc.	95	2026-10-01	2026-10-15
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring Spirometer, Oximeter, Scale - Fibrotic Interstitial Lung Disease, IPF and PPF	Not applicable	Recruiting	University of California, San Francisco	200	2026-10-01	2026-10-09
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets NAL ER, Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Recruiting	Trevi Therapeutics	201	2026-09-30	2026-10-09
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis Metformin, Matching Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Not yet recruiting	University of Massachusetts, Worcester	800	2026-09-28	2026-09-08
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) INS018_055 tablets, Placebo - Idiopathic Pulmonary Fibrosis	Phase 3	Recruiting	InSilico Medicine Hong Kong Limited	320	2026-09-09	2026-10-13
New Diagnostic Approaches in the Management of Inflammatory Lung Diseases Integrated Precision Medicine Platform - Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis	Not applicable	Not yet recruiting	Fondazione Don Carlo Gnocchi ETS	200	2026-09-01	2026-07-23
Blood Cell Count Derived Inflammatory Indexes in Acute Exacerbation of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis		Not yet recruiting	Assiut University	70	2026-09-01	2026-08-24
A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis AK3280, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF)	Phase 3	Not yet recruiting	Shanghai Ark Biopharmaceutical Co., Ltd.	263	2026-08-31	2026-07-22
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3 - Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Not yet recruiting	Haisco Pharmaceutical Group Co., Ltd.	175	2026-08-25	2026-07-27
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms Pulmonary Embolism, Interstitial Lung Disease		Not yet recruiting	Assiut University	70	2026-08-01	2026-07-27
Dose-Escalation Study of Artesunate Patients With IPF Artesuante, Placebo capsules - Idiopathic Pulmonary Fibrosis	Phase 1	Recruiting	Joseph C. Wu	15	2026-08-01	2026-08-11
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis		Completed	Boehringer Ingelheim	122	2026-08-01	2026-10-13
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis Antifibrotic therapy - Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis		Not yet recruiting	Bristol-Myers Squibb	40	2026-08-01	2026-07-23
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis CHF10067, Placebo - Idiopathic Pulmonary Fibrosis	Phase 2	Recruiting	Chiesi Farmaceutici S.p.A.	240	2026-07-08	2026-10-16
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung		Not yet recruiting	Cosmos Rx, Inc	100	2026-07-01	2026-05-29
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis SYH2059 Tablets, Placebo - Idiopathic Pulmonary Fibrosis	Phase 2	Not yet recruiting	InnovStone Therapeutics Limited	156	2026-06-30	2026-05-20

Showing 20 of 577. Sign in to see all of them.

Narrower conditions

Lung Diseases, Interstitial (105)  ·  Pulmonary Fibrosis (89)  ·  Idiopathic Interstitial Pneumonias (27)  ·  Pulmonary Disease, Chronic Obstructive (26)  ·  Lung Diseases (25)  ·  Fibrosis (24)  ·  Cough (13)  ·  Hypertension, Pulmonary (13)  ·  Sarcoidosis (13)  ·  Alveolitis, Extrinsic Allergic (11)  ·  Connective Tissue Diseases (10)  ·  Motor Activity (10)  ·  Respiratory Tract Diseases (10)  ·  Dyspnea (9)

Broader conditions

Respiratory Tract Diseases (567)  ·  Lung Diseases (552)  ·  Pulmonary Fibrosis (488)  ·  Lung Diseases, Interstitial (472)  ·  Pathological Conditions, Signs and Symptoms (159)  ·  Pathologic Processes (134)  ·  Fibrosis (78)  ·  Immune System Diseases (35)  ·  Disease Attributes (34)  ·  Hypersensitivity (28)  ·  Lung Diseases, Obstructive (28)  ·  Chronic Disease (27)  ·  Signs and Symptoms (27)  ·  Respiration Disorders (26)  ·  Signs and Symptoms, Respiratory (24)

Interventions

pirfenidone (41)  ·  nintedanib (36)  ·  Sildenafil Citrate (8)  ·  Blood Specimen Collection (6)  ·  BI 1015550 (5)  ·  Bosentan (5)  ·  Nalbuphine (5)  ·  pamrevlumab (5)  ·  treprostinil (5)  ·  Acetylcysteine (4)  ·  Exercise (4)  ·  Interferon-gamma (4)  ·  LY2940680 (4)  ·  Oxygen (4)  ·  PRM-151 (4)

Sponsors

Boehringer Ingelheim (35)  ·  Hoffmann-La Roche (16)  ·  Royal Brompton & Harefield NHS Foundation Trust (11)  ·  Bristol-Myers Squibb (9)  ·  Duke University (8)  ·  Genentech, Inc. (7)  ·  GlaxoSmithKline (7)  ·  Sunshine Lake Pharma Co., Ltd. (7)  ·  Actelion (6)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  InterMune (6)  ·  National Jewish Health (6)  ·  University of Alabama at Birmingham (6)  ·  Assiut University (5)  ·  AstraZeneca (5)

Countries

United States (238)  ·  United Kingdom (103)  ·  Germany (75)  ·  France (70)  ·  Italy (69)  ·  Canada (66)  ·  China (66)  ·  Australia (65)  ·  Spain (58)  ·  South Korea (51)  ·  Netherlands (42)  ·  Belgium (40)  ·  Denmark (34)  ·  Greece (33)  ·  Turkey (Türkiye) (32)

Top investigators

Ganesh Raghu, MD (7)  ·  Imre Noth, MD (5)  ·  Fernando Martinez, MD (4)  ·  Aliaa Barakat, PhD (3)  ·  Danielle Antin-Ozerkis, MD (3)  ·  David A Schwartz, MD (3)  ·  Francesco Amati, MD (3)  ·  James Loyd, MD (3)  ·  Jay Ryu, MD (3)

Results publications

PMID 35688625, PMID 37391667, PMID 26835133, PMID 31047956, PMID 33434107, PMID 25890798, PMID 26111071, PMID 26968970, PMID 27708114, PMID 28388260, PMID 30072107, PMID 30116539, PMID 30472023, PMID 31153107, PMID 31401786, PMID 21571362, PMID 24177001, PMID 25770676, PMID 26083430, PMID 28657784, PMID 28883090, PMID 29150411, PMID 31179008, PMID 32160670, PMID 33463535, PMID 33902584, PMID 36724330, PMID 37159034, PMID 38238788, PMID 38288082, PMID 38509495, PMID 40355288, PMID 41345848, PMID 42548365, PMID 42776606, PMID 10380242, PMID 10501650, PMID 12091180, PMID 16306520, PMID 16634026, PMID 16806873, PMID 16883006, PMID 17356110, PMID 17585107, PMID 17675522, PMID 17901413, PMID 18245143, PMID 18432536, PMID 18669816, PMID 18808608

NIH funding

2015 (9), 2023 (8), 2019 (6), 2017 (4), 2018 (4), 2025 (4), 2014 (3), 2016 (3), U10HL080413 (3), R01HL097163 (2), 1RC2HL101740-01 (1), 1UM1HL119089 (1), K23HL086714 (1), K23HL092227 (1), K23HL175213 (1)